Price (delayed)
$59.02
Market cap
$3.25B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.99
Enterprise value
$3.22B
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which
There are no recent dividends present for ACLX.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.